200 related articles for article (PubMed ID: 9253368)
1. Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy.
Colao A; Lombardi G
J Clin Endocrinol Metab; 1997 Aug; 82(8):2756. PubMed ID: 9253368
[No Abstract] [Full Text] [Related]
2. Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy.
Delgrange E; Donckier J
J Clin Endocrinol Metab; 1997 Aug; 82(8):2755-6. PubMed ID: 9253367
[No Abstract] [Full Text] [Related]
3. Cabergoline and quinagolide therapy for prolactinomas.
Webster J
Clin Endocrinol (Oxf); 2000 Nov; 53(5):549-50. PubMed ID: 11106914
[No Abstract] [Full Text] [Related]
4. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
[TBL] [Abstract][Full Text] [Related]
5. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
[TBL] [Abstract][Full Text] [Related]
6. Prolactinomas and pregnancy.
Molitch ME
Clin Endocrinol (Oxf); 2010 Aug; 73(2):147-8. PubMed ID: 20550542
[No Abstract] [Full Text] [Related]
7. Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists.
De Sousa SM; Chapman IM; Falhammar H; Torpy DJ
Endocrine; 2017 Feb; 55(2):618-624. PubMed ID: 27601019
[TBL] [Abstract][Full Text] [Related]
8. Late development of resistance to bromocriptine in a patient with macroprolactinoma.
Delgrange E; Crabbé J; Donckier J
Horm Res; 1998; 49(5):250-3. PubMed ID: 9568811
[TBL] [Abstract][Full Text] [Related]
9. Cabergoline, a hopeful medicine for prolactinomas and non-tumoral hyperprolactinemia.
Miki N
Intern Med; 2001 Sep; 40(9):845-6. PubMed ID: 11579939
[No Abstract] [Full Text] [Related]
10. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine.
Delgrange E; Maiter D; Donckier J
Eur J Endocrinol; 1996 Apr; 134(4):454-6. PubMed ID: 8640297
[TBL] [Abstract][Full Text] [Related]
11. Giant pubertal prolactinoma: Complete resolution following short term carbegoline treatment.
Oguz A; Tuzun D; Sahin M; Gul K
Niger J Clin Pract; 2016; 19(5):685-7. PubMed ID: 27538562
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of macroprolactinomas with quinagolide (Norprolac)].
Tabarin A; Catargi B
Ann Endocrinol (Paris); 1997; 58(2):87-94. PubMed ID: 9239226
[TBL] [Abstract][Full Text] [Related]
13. Proptosis as the presenting sign of giant prolactinoma in a prepubertal boy: successful resolution of hydrocephalus by use of medical therapy.
Cackett P; Eunson G; Bath L; Mulvihill A
Future Oncol; 2012 Dec; 8(12):1621-6. PubMed ID: 23231524
[TBL] [Abstract][Full Text] [Related]
14. [Quinagolide and macroprolactinomas a progress?].
Jaquet P
Ann Endocrinol (Paris); 1997; 58(2):83-5. PubMed ID: 9239225
[No Abstract] [Full Text] [Related]
15. [Efficacy of cabergoline in the treatment of macroprolactinoma].
Dupuy O; Le Marec E; Mayaudon H; Rilminger H; Bordier L; Bauduceau B
Presse Med; 2003 Jan; 32(2):71-2. PubMed ID: 12653031
[No Abstract] [Full Text] [Related]
16. Dopamine receptor agonists for treating prolactinomas.
Colao A; di Sarno A; Pivonello R; di Somma C; Lombardi G
Expert Opin Investig Drugs; 2002 Jun; 11(6):787-800. PubMed ID: 12036422
[TBL] [Abstract][Full Text] [Related]
17. The use of high-dose daily cabergoline in an adolescent patient with macroprolactinoma.
Howell DL; Wasilewski K; Mazewski CM; Hudgins RJ; Meacham LR
J Pediatr Hematol Oncol; 2005 Jun; 27(6):326-9. PubMed ID: 15956887
[TBL] [Abstract][Full Text] [Related]
18. [Prolactinoma and pregnancy].
Trifonov I
Akush Ginekol (Sofiia); 2004; 43 Suppl 2():16-22. PubMed ID: 15518268
[No Abstract] [Full Text] [Related]
19. Cabergoline resistance in pediatric prolactinomas.
Spinks JJ; Ryan FJ
J Pediatr Hematol Oncol; 2009 May; 31(5):377-9. PubMed ID: 19415025
[TBL] [Abstract][Full Text] [Related]
20. Toward the establishment of a clinical prediction rule for response of prolactinomas to cabergoline.
Delgrange E; Donckier JE
J Clin Endocrinol Metab; 1999 Dec; 84(12):4746-7. PubMed ID: 10599747
[No Abstract] [Full Text] [Related]
[Next] [New Search]